SCHEMBL932993

SCHEMBL932993

ON1C=CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL27347124 0.89
SCHEMBL5666576 0.84
SCHEMBL20184137 0.79
SCHEMBL25433863 0.77
SCHEMBL25432325 0.70
SCHEMBL25432840 0.69
SCHEMBL25433976 0.65
SCHEMBL7081895 0.65
SCHEMBL20162411 0.65
SCHEMBL4022349 0.64 SLC6A2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704832-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS Biohaven Therapeutics Ltd. (VG) 2026-03-11 EP claimed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 US claimed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 US claimed
WO-2024227119-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-10-31 WO claimed
US-20240342293-A1 ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS YALE UNIVERSITY 2024-10-17 US claimed
US-12083181-B2 Bi-functional molecules to degrade circulating proteins YALE UNIVERSITY (US) 2024-09-10 US claimed
WO-2024167900-A2 BIFUNCTIONAL MOLECULES TO TARGET DEGRADATION OF TUMOR NECROSIS FACTOR BIOHAVEN THERAPEUTICS LTD. (VG) 2024-08-15 WO claimed
WO-2024167879-A1 BIFUNCTIONAL MOLECULES TO TARGET DEGRADATION OF INTERLEUKIN 17A (IL-17A) BIOHAVEN THERAPEUTICS LTD. (VG) 2024-08-15 WO claimed
US-20240181067-A1 TARGETED BIFUNCTIONAL DEGRADERS AND METHODS USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-06 US claimed
US-20240148885-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-05-09 US claimed
EP-3773729-A1 BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS Yale University (US) 2021-02-17 EP claimed
CN-112236169-A Bifunctional small molecules targeting selective degradation of circulating proteins 耶鲁大学 2021-01-15 CN claimed
CN-111448520-A Photoresist stripper composition 汉高股份有限及两合公司 2020-07-24 CN claimed
WO-2019199621-A1 BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS YALE UNIVERSITY (US) 2019-10-17 WO claimed
EP-1626748-B1 MOISTURE CURABLE MATERIALS FOR DELIVERY OF AGENTS, METHODS, AND MEDICAL DEVICES MEDTRONIC INC (US) 2012-07-11 EP claimed
EP-1429763-B1 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-05-30 EP claimed
EP-0646595-B1 Nucleic acid binding oligomers having C-branches for therapy and diagnosis BAYER AG (DE) 1998-11-04 EP claimed
EP-0567827-A1 Process for preparation of N-hydroxyazoles BASF Aktiengesellschaft (DE) 1993-11-03 EP claimed
EP-0281692-A1 Additive for lubricants and hydrocarbon fuels comprising reaction products of olefins, sulfur, hydrogen sulfide and nitrogen containing polymeric compounds MOBIL OIL CORPORATION (US) 1988-09-14 EP claimed
US-4661274-A Additive for lubricants and hydrocarbon fuels comprising reaction products of olefins, sulfur, hydrogen sulfide and nitrogen containing polymeric compounds MOBIL OIL CORPORATION (US) 1987-04-28 US claimed